Antivenom therapy for snakebites in children: Is there evidence?

Current Opinion in Pediatrics

Volumn 17, Issue 2, 2005, Pages 234-238

  Schmidt, James M ^a,b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b CHILDREN S HOSPITAL OF THE KING S DAUGHTERS   (United States)

Author keywords

Antivenins; Antivenoms; Crotalid venom; Crotaline venom; Immunoglobulin fragments; Pediatrics; Snake bites

Indexed keywords

CROFAB; DIGOXIN ANTIBODY F(AB) FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCROTALINE; SPIDER VENOM ANTISERUM;

CHILD; CLINICAL TRIAL; DIAPHORESIS; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ENVENOMATION; FLUSHING; FOLLOW UP; HUMAN; PEDIATRICS; PHENOMENOLOGY; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SNAKEBITE; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME; WHEEZING;

ANTIVENINS; CHILD; CROTALID VENOMS; EXANTHEMA; HUMANS; IMMUNOGLOBULIN FRAGMENTS; PRURITUS; SNAKE BITES; SNAKE VENOMS; TREATMENT OUTCOME;

EID: 17144391131     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000152621.67049.f2     Document Type: Review

References (26)

1. Watson WA, Litovitz TL, Klein-Schwartz W, et al. 2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003; 22:335-404.
2. Hoyt BT, Rasmussen R, Giffin S, Smilkstein MJ. Poison center data accuracy: a comparison of rural hospital chart data with the TESS database. Toxic Exposure Surveillance System. Acad Emerg Med 1999; 6:851-855.
3. Gold BS, Dart RC, Barish RA. Bites of venomous snakes. N Engl J Med 2002; 347:347-356.
4. Offerman SR, Bush SP, Moynihan JA, Clark RF. Crotaline Fab antivenom for the treatment of children with rattlesnake envenomation. Pediatrics 2002; 110:968-971.
5. Gold BS. North American snake envenomation: diagnosis, treatment, and management. Emerg Med Clin North Am 2004; 22:423-443. A very complete review of North American venomous snakes and management of envenomation. Includes discussion of ACP and Crofab, based on data current up through the two prerelease clinical trials.
6. Dart RC, Seifert SA, Boyer LV, et al. A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med 2001; 161: 2030-2036.
7. Crofab [package insert]. Nashville, Tennessee: Protherics, Inc.; 2000.
8. Consroe P, Egen NB, Russell FE, et al. Comparison of a new ovine antigen binding fragment (Fab) antivenom for United States Crotalidae with the commercial antivenom for protection against venom-induced lethality in mice. Am J Trop Med Hyg 1995; 53:507-510.
9. Dart RC, Seifert SA, Carroll L, et al. Affinity-purified, mixed monospecific crotalid antivenom ovine Fab for the treatment of crotalid venom poisoning. Ann Emerg Med 1997; 30:33-39.
10. Bush SP, Green SM, Moynihan JA, et al. Crotalidae polyvalent immune Fab (ovine) antivenom is efficacious for envenomations by Southern Pacific rattlesnakes (Crotalus helleri). Ann Emerg Med 2002; 40:619-624.
11. Ruha AM, Curry SC, Beuhler M. Initial postmarketing experience with crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation. Ann Emerg Med 2002; 39:609-615.
12. Lavonas EJ, Gerardo CJ, O'Malley G, et al. Initial experience with Crotalidae polyvalent immune Fab (ovine) antivenom in the treatment of copperhead snakebite. Ann Emerg Med 2004; 43:200-206. A large, retrospective series of envenomations and the only study focusing on copperhead envenomations.
13. Bogdan GM. Recurrent coagulopathy after antivenom treatment for crotalid snakebite. South Med J 2000; 93:562-566.
14. Boyer LV, Seifert SA, Cain JS. Recurence phenomena after immunoglobulin therapy for snake envenomations: Part 2. Guidelines for clinical management with crotaline Fab antivenom. Ann Emerg Med 2001; 37: 196-201.
15. Seifert SA, Boyer LV. Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies. Ann Emerg Med 2001; 37:189-195.
16. Offerman SR, Barry JD, Schneir A, Clark RF. Biphasic rattlesnake venom-induced thrombocytopenia. J Emerg Mec 2003; 24:289-293. A case report of recurrent thrombocytopenia refractory to Crofab with discussion of venom-induced thrombocytopenia.
17. Gold BS. Refractory thrombocytopenia despite treatment for rattlesnake envenomation. N Engl J Med 2004; 350:1912-1913.
18. Caravati EM. Copperhead bites and Crotalidae polyvalent immune Fab (ovine): routine use requires evidence of improved outcomes. Ann Emerg Med 2004; 43:207-208.
19. Yip L. Rational use of crotalidae polyvalent immune Fab (ovine) in the management of crotaline bite. Ann Emerg Med 2002; 39:648-650.
20. Curry SC, Kunkel DB. Death from a rattlesnake bite. Am J Emerg Med 1985; 3:227-235.
21. Weber RA, White RR. Crotalidae envenomation in children. Ann Plast Surg 1993; 31:141-145.
22. LoVecchio F, DeBus DM. Snakebite envenomation in children: a 10-year retrospective review. Wilderness Environ Med 2001; 12:184-189.
23. Behm MO, Kearns GL. Crotaline Fab antivenom for treatment of children with rattlesnake envenomation. Pediatrics 2003; 112:1458-1459. A letter to the editor emphasizing the need and the rationale for dosing Crofab for children the same as for adults rather than dosing based on weight.
24. Mickey AR, Wenger TL, Carpenter VP, et al. Digoxin immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol 1991; 17: 590-598.
25. Clark RF, McKinney PE, Chase PB, Waltei FG. Immediate and delayed allergic reactions to Crotalidae polyvalent immune Fab (ovine) antivenom. Ann Emerg Med 2002; 39:671-676.
26. Holstege CP. Immediate hypersensitivity reaction associated with the rapid infusion of Crotalidae polyvalent immune Fab (ovine). Ann Emerg Med 2002; 39:609-615.